Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis
Frontiers in Pharmacology · 17.02.2026 · 17
DOI: 10.3389/fphar.2026.1719493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.02.2026. Verfasst von Yating Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kunshan Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).
Methods
We searched PubMed, Web of Science, Cochrane Library, and Embase from inception to 13 August 2025. We included studies reporting changes in best-corrected visual acuity (BCVA), changes in central subfield thickness (CST), changes in the leakage lesion of choroidal neovascularization (CNV), and adverse events from baseline to endpoint. All statistical analyses were performed using Stata 18.0 software and assessed the certainty of evidence for each outcome using the GRADE approach.
Results
A total of seven studies involving 2,829 participants were included. There were no statistically significant differences in visual and anatomical outcomes between the aflibercept biosimilars (SB15, P041, SDZ-AFL, AVT06, SCD411, ABP 938, and QL1207) and the reference aflibercept. No significant differences were detected between aflibercept biosimilars and the reference aflibercept with respect to serious ocular and non-ocular adverse events [relative risk (RR) = 1.71, 95% confidence interval (CI): 0.70, 4.19; I 2 = 0.0%, P = 0.913; RR = 1.08, 95% CI: 0.82, 1.42; I 2 = 0.0%, P = 0.936, respectively). Although a slightly higher rate of treatment-emergent adverse events (TEAEs) was noted in the biosimilar group (RR = 1.07, 95% CI: 1.00–1.15; I 2 = 26.1%), the difference was not statistically significant ( P = 0.248).
Conclusion
Based on the seven included randomized controlled clinical trials, aflibercept biosimilars demonstrated comparable safety and efficacy to the reference aflibercept. Future research requires more rigorous studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Kunshan Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China.
- Department of Ophthalmology, Shanghai University Affiliated Heping Eye Hospital, Shanghai, China.
- Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease,Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, C…
- Department of Ophthalmology, Affiliated Xinhua Hospital of Dalian University, Dalian, Liaoning, China.
Zitieren
APA
Zhou, Y., Zhan, Z., Wang, Z., & Liu, C. (2026). Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1719493
Vancouver
Zhou Y, Zhan Z, Wang Z, Liu C. Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1719493
BibTeX
@article{Zhou2026,
author = {Zhou, Yating and Zhan, Zongyue and Wang, Zixun and Liu, Chen},
title = {Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1719493}
}
EUVIMED